Mar 18 |
Oculis Holding reports Q4 results
|
Mar 18 |
Oculis Reports Q4 and Full Year 2023 Financial Results and Update on Company Progress
|
Feb 28 |
Oculis Provides Updates at R&D Day on Late-Stage Clinical Trials and Announces Key Leadership Appointments
|
Jan 29 |
Oculis to Present at Upcoming February Investor Conferences
|
Jan 22 |
Oculis to Host In-Person & Virtual R&D Day in New York on February 28, 2024
|
Dec 18 |
Oculis Announces First Patient First Visit in Phase 3 DIAMOND-1 Trial of OCS-01 Eye Drop in Diabetic Macular Edema
|
Dec 7 |
Oculis Announces First Patient First Visit in Phase 2b RELIEF Trial of Topical Anti-TNFα Licaminlimab (OCS-02) in Dry Eye Disease
|